Research ExplorerPublicationsEvaluation of the antipruritic effects of topical pimecrolim...

Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial

Standard

Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. / Siepmann, Dorothee; Lotts, Tobias; Blome, Christine; Braeutigam, Matthias; Phan, Ngoc Quan; Butterfass-Bahloul, Trude; Augustin, Matthias; Luger, Thomas A; Ständer, Sonja.

In: DERMATOLOGY, Vol. 227, No. 4, 01.01.2013, p. 353-60.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Siepmann, D, Lotts, T, Blome, C, Braeutigam, M, Phan, NQ, Butterfass-Bahloul, T, Augustin, M, Luger, TA & Ständer, S 2013, 'Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial', DERMATOLOGY, vol. 227, no. 4, pp. 353-60. https://doi.org/10.1159/000355671

APA

Siepmann, D., Lotts, T., Blome, C., Braeutigam, M., Phan, N. Q., Butterfass-Bahloul, T., Augustin, M., Luger, T. A., & Ständer, S. (2013). Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. DERMATOLOGY, 227(4), 353-60. https://doi.org/10.1159/000355671

Vancouver

Siepmann D, Lotts T, Blome C, Braeutigam M, Phan NQ, Butterfass-Bahloul T et al. Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. DERMATOLOGY. 2013 Jan 1;227(4):353-60. https://doi.org/10.1159/000355671

Bibtex

@article{6f884262864043cfa3f5f339781cc7ef,
title = "Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial",
abstract = "BACKGROUND: In the treatment of atopic dermatitis, pimecrolimus has high antipruritic effects.OBJECTIVE: To investigate the efficacy of 1% pimecrolimus cream in comparison to 1% hydrocortisone cream in non-atopic prurigo nodularis (PN).METHODS: A randomized, controlled, double-blind study with intraindividual randomization was done in 30 patients (17 females, 13 males; mean age 58.5 years) with PN.RESULTS: Pruritus intensity decreased significantly (p < 0.001) on both treated sides as early as after 10 days of treatment; scratch lesions improved (p < 0.001). Quality of life as assessed by the Dermatology Life Quality Index improved significantly. However, a significant advantage of pimecrolimus over hydrocortisone was not found.CONCLUSION: The results suggest that the non-steroid pimecrolimus is an effective alternative for PN treatment.",
author = "Dorothee Siepmann and Tobias Lotts and Christine Blome and Matthias Braeutigam and Phan, {Ngoc Quan} and Trude Butterfass-Bahloul and Matthias Augustin and Luger, {Thomas A} and Sonja St{\"a}nder",
year = "2013",
month = jan,
day = "1",
doi = "10.1159/000355671",
language = "English",
volume = "227",
pages = "353--60",
journal = "DERMATOLOGY",
issn = "1018-8665",
publisher = "S. Karger AG",
number = "4",

}

RIS

TY - JOUR

T1 - Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial

AU - Siepmann, Dorothee

AU - Lotts, Tobias

AU - Blome, Christine

AU - Braeutigam, Matthias

AU - Phan, Ngoc Quan

AU - Butterfass-Bahloul, Trude

AU - Augustin, Matthias

AU - Luger, Thomas A

AU - Ständer, Sonja

PY - 2013/1/1

Y1 - 2013/1/1

N2 - BACKGROUND: In the treatment of atopic dermatitis, pimecrolimus has high antipruritic effects.OBJECTIVE: To investigate the efficacy of 1% pimecrolimus cream in comparison to 1% hydrocortisone cream in non-atopic prurigo nodularis (PN).METHODS: A randomized, controlled, double-blind study with intraindividual randomization was done in 30 patients (17 females, 13 males; mean age 58.5 years) with PN.RESULTS: Pruritus intensity decreased significantly (p < 0.001) on both treated sides as early as after 10 days of treatment; scratch lesions improved (p < 0.001). Quality of life as assessed by the Dermatology Life Quality Index improved significantly. However, a significant advantage of pimecrolimus over hydrocortisone was not found.CONCLUSION: The results suggest that the non-steroid pimecrolimus is an effective alternative for PN treatment.

AB - BACKGROUND: In the treatment of atopic dermatitis, pimecrolimus has high antipruritic effects.OBJECTIVE: To investigate the efficacy of 1% pimecrolimus cream in comparison to 1% hydrocortisone cream in non-atopic prurigo nodularis (PN).METHODS: A randomized, controlled, double-blind study with intraindividual randomization was done in 30 patients (17 females, 13 males; mean age 58.5 years) with PN.RESULTS: Pruritus intensity decreased significantly (p < 0.001) on both treated sides as early as after 10 days of treatment; scratch lesions improved (p < 0.001). Quality of life as assessed by the Dermatology Life Quality Index improved significantly. However, a significant advantage of pimecrolimus over hydrocortisone was not found.CONCLUSION: The results suggest that the non-steroid pimecrolimus is an effective alternative for PN treatment.

U2 - 10.1159/000355671

DO - 10.1159/000355671

M3 - SCORING: Journal article

C2 - 24281309

VL - 227

SP - 353

EP - 360

JO - DERMATOLOGY

JF - DERMATOLOGY

SN - 1018-8665

IS - 4

ER -